The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market. The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023. The global longevity and anti-senescence therapy market has been segmented by the following therapies: Senolytic drug therapy, Gene therapy, Immunotherapy and Other therapies which includes stem cell-based therapies, etc.
Unilever Plc plans to sharpen its focus on health and hygiene and sell off slow-growth brands as it weighs making a higher offer for GlaxoSmithKline Plc’s consumer unit.
A Parkinson’s disease gene turns out to provide the key to modify diseases related to immunoageing
A third member of a panel of outside advisers to the U.S. Food and Drug Administration has resigned in protest over the agency’s decision to approve Biogen Inc’s (BIIB.O) Alzheimer’s disease treatment despite the committee’s recommendation against doing so.